Hot Natural Products & Bioactive Compounds
BioCrick offers high-purity natural products and bioactive compounds for scientific research. Our natural product collection includes compounds derived from plants, microorganisms and other biological sources and is widely used in pharmacological, biochemical and drug discovery research.
Natural products remain an important source of bioactive molecules and drug leads. BioCrick provides researchers with high-quality natural product compounds together with catalog numbers, product information and biological activity data.
Hot Products from BioCrick
Showing 313 - 320 of 9359 hot products
| Catalog No. | Product Name |
|---|---|
| BCC2119 | GM 6001 |
|
Broad spectrum MMP inhibitor. Reduces infarct volume following middle cerebral artery occlusion in an ischemic mouse model. Also inhibits human skin fibroblast collagenase (K<sub>i</sub> = 0.4 nM).
|
|
| BCC2120 | NSC 405020 |
|
Membrane type-1 matrix metalloproteinase (MT1-MMP) inhibitor (IC<sub>50</sub> > 100 <span class='symbol'>μ</span>mol/L). Directly interacts with the hemopexin domain (PEX) of MT1-MMP, affecting homodimerization and repressing its pro-tumorigenic activity <em>in vivo</em>. Displays no effect on the catalytic activity of MT1-MMP or MMP-2.
|
|
| BCC2121 | 17-AAG (KOS953) |
|
Inhibitor of heat shock protein 90 (Hsp90) chaperone activity, and an analog of geldanamycin. Subsequently inhibits the activity of oncogenic proteins such as p185<sup>erbB-2</sup> (IC<sub>50</sub> = 31 nM), N-ras, Ki-ras and c-Akt. Antitumor <em>in vivo</em>. Also protects neuroprogenitor cells against stress-induced apoptosis at low concentrations (10 nM) <em>in vitro</em>.
|
|
| BCC2124 | BIIB021 |
|
Selective, Hsp90 competitive inhibitor (Ki = 1.7 nM). Displays no significant activity at a range of ATP-binding kinases or Na+K+ ATPase. Induces degradation of HER-2 in vitro (EC50 = 38 nM in MCF-7 cells). Inhibits growth and promotes cell death in a variety of human tumor cells. Orally bioavailable.
|
|
| BCC2125 | Geldanamycin |
|
Selectively inhibits heat shock protein 90 (Hsp90). Binds to the ATP site of Hsp90 (K<sub>d</sub> = 1.2 <span class='symbol'>μ</span>M) and inhibits its chaperone activity. Consequently inhibits activities of oncogenic kinases (e.g. src, Raf), p53 and steroid receptors. Demonstrates antiproliferative effect on breast cancer stem-like cells.
|
|
| BCC2131 | Radicicol |
|
Antifungal antibiotic. Inhibits heat shock protein 90 (Hsp90) activity by binding to the ATP-binding pocket, subsequently suppressing cell transformation induced by src, ras and mos. Represses estrogen receptor transcriptional activity and inhibits angiogenesis.
|
|
| BCC2135 | Fluorouracil (Adrucil) |
|
Anticancer agent. Metabolized to form fluorodeoxyuridine monophosphate (FdUMP), fluorodeoxyuridine triphosphate (FdUTP) and fluorouridine (FUTP). FdUMP inhibits thymidylate synthase, causing a reduction in dTMP synthesis. FUTP and FdUTP are misincorporated into RNA and DNA respectively.
|
|
| BCC2140 | Captopril |
|
Angiotensin-converting enzyme (ACE) inhibitor (IC<sub>50</sub> = 0.022 <span class='symbol'>μ</span>M). Also displays reversible, competitive inhibition of leukotriene A<sub>4</sub> (LTA<sub>4</sub>) hydrolase.
|
|